Evidence map›Paper›PMID 42882828›Full record

ArticleCancers2026

GAS5 Downregulation Promotes the Progression of Triple-Negative Breast Cancer by Regulating Tumor Cells-MDSCs Crosstalk.

Junze Du, Xingyun He, Lingfeng Tang, Hao Liu, Qingqiu Chen, Sisi Li, Gang Tu, Shichao Li

Abstract read
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Junze DuChongqing Key Laboratory of Molecular Oncology and Epigenetics, Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Xingyun HeDepartment of Radiology, The First Affiliated Hospital of Army Medical University, Chongqing 400038, China.ORCID 0009-0006-7917-8996
Lingfeng TangChongqing Key Laboratory of Molecular Oncology and Epigenetics, Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Hao LiuChongqing Key Laboratory of Molecular Oncology and Epigenetics, Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Qingqiu ChenDepartment of Breast and Thyroid Surgery, The First Affiliated Hospital of Army Medical University, Chongqing 400038, China.
Sisi LiThe Biobank of Southwest Hospital, The First Affiliated Hospital of Army Medical University, Chongqing 400038, China.
Gang TuChongqing Key Laboratory of Molecular Oncology and Epigenetics, Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Shichao LiDepartment of Breast and Thyroid Surgery, The First Affiliated Hospital of Army Medical University, Chongqing 400038, China.ORCID 0009-0004-0119-7658

Funding

General Program Project of Chongqing Shapingba District Science and Technology Bureau 2025180
6 · The paper itself

Abstract

backgroundTriple-negative breast cancer (TNBC) is exceptionally aggressive, with a high recurrence rate, resistance to chemotherapy, and a tendency to metastasize. The long non-coding RNA growth arrest-specific 5 (GAS5) is associated with TNBC progression; however, the specific mechanism still requires further exploration.

methodsIntegrative bioinformatics analyses and qRT-PCR were used to investigate the significant downregulation of GAS5 in TNBC cells and tissues. The functional role and molecular mechanism of GAS5 in inhibiting the progression of TNBC and increasing sensitivity to chemotherapy were investigated using in vitro experiments, including qPCR, Western blot, CCK8 assay, Transwell, Chemotaxis assays, RNA immunoprecipitation, m6A-RNA immunoprecipitation, Chromatin immunoprecipitation, Flow cytometry, ELISA, and Luciferase reporter assays, and in vivo experiments using tumor xenografts.

resultsGAS5 was significantly downregulated in TNBC cells and tissues, as well as in chemotherapy-resistant conditions. Functional assays revealed that overexpression of GAS5 attenuated the progression of TNBC and increased their sensitivity to docetaxel (DTX) both in vitro and in vivo. Furthermore, we confirmed that GAS5 recruited YTHDF2 to target MYBL2, which in turn downregulated the chemokine CCL2, which reduced the recruitment of myeloid-derived immunosuppressive cells (MDSCs). In addition, IL-6 from MDSCs downregulated GAS5 to promote TNBC growth and attenuate the sensitivity of TNBC to DTX through the STAT3/UPF1 axis, forming a feedback loop between tumor cells and MDSCs.

conclusionsThese findings illustrated the significance of the GAS5-mediated mutual regulatory pathway between tumor cells and MDSCs in TNBC and provide new avenues for the development of targeted therapies in TNBC.

Indexed as

growth arrest-specific 5 (GAS5)IL-6/STAT3/UPF1 axismyeloid-derived immunosuppressor cells (MDSCs)triple-negative breast cancer (TNBC)YTHDF2/MYBL2/CCL2 axis

Identifiers

PMID42882828
PMCPMC13663935

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.